9 results about "Nod mouse" patented technology

The invention discloses an application of a Pik3cb inhibitor in treatment of Sjogren's disease. Experiments prove that the Pik3cb inhibitor TGX-221 can reduce the number, activation and chemotaxis of NOD mouse B cells of a Sjogren's disease model mouse, plasma cell differentiation and antibody secretion, improve the immune microenvironment of the submaxillary gland of the Sjogren's disease model mouse, reduce the infiltration degree of submaxillary gland lymphocytes and promote the salivary secretion function; and after the Pik3cb is over-expressed, the symptom and pathology of the Sjogren's disease are aggravated. Therefore, the Pik3cb inhibitor can be used for treating the Sjogren's disease. The invention provides a new thought for research and development of medicines for treating the Sjogren's disease, and has important application value.

The application provides a traditional Chinese medicine composition for treating or improving Sjogren's syndrome, and belongs to the technical field of traditional Chinese medicine pharmacy.The traditional Chinese medicine composition takes asparagus, lily and mulberry as monarch drugs, takes honeysuckle, semen astragali, rush and radix codonopsis as minister drugs, takes turmeric and atractylodes as auxiliary drugs, and takes licorice as a guide drug, and the drugs are combined to have the effects of nourishing yin and moistening dryness, clearing heat and dredging collaterals, tonifying qi and invigorating the spleen, and promoting blood circulation and improving eyesight.The traditional Chinese medicine composition can significantly reduce the water consumption of NOD mice, increase the saliva amount of NOD mice, significantly down-regulate the levels of inflammatory factors TNF-alpha, IL-17 and IL-1beta in the serum of NOD mice, improve the gland structure and lymphocyte infiltration in the submandibular gland tissue of NOD mice, and reduce the submandibular gland injury.In addition, the traditional Chinese medicine composition can significantly reduce the ESSDAI and ESSPRI scores of Sjogren's syndrome patients, improve the clinical symptoms such as dry mouth, dry eyes and salivary gland swelling of the patients, has a high total effective rate in clinical treatment, and can be further developed and researched as a drug for treating Sjogren's syndrome.

The invention provides application of agomelatine in preparation of a medicine for treating sicca syndrome, and relates to the technical field of biomedicine, agomelatine is a novel anti-depression medicine, and the main action mechanism of agomelatine is that anti-depression and anti-anxiety effects are achieved by activating melatonin receptors (MT1 and MT2) and antagonizing a 5-HT2c receptor. According to the application, an 8w-old NOD mouse is selected as a sicca syndrome model mouse, and meanwhile, an ICR mouse is selected as a normal mouse of the same control. NOD mice are randomly divided into a blank control group, a hydroxychloroquine (HCQ) treatment group (50 mg / kg), a melatonin (MLT) treatment group (15 mg / kg) and an agomelatine (AGO) treatment group (50 mg / kg). And observing the disease degree of the sicca syndrome mouse after 4W treatment. A specific verification experiment proves that the agomelatine in the application can be used for remarkably improving the sicca syndrome.

The invention discloses application of 5-methyltetrahydrofolic acid in regulating effect CD8 + T cells, belongs to the technical field of biological medicines, and provides and verifies the application of the 5-methyltetrahydrofolic acid in regulating effect CD8 + T cells for the first time. PBS-treated wild type NOD mouse CD8 + T primary cells, 5-methyltetrahydrofolic acid-treated wild type NOD mouse CD8 + T primary cells, common feed-fed wild type NOD mice and 5-methyltetrahydrofolic acid-containing feed-fed wild type NOD mice are taken as research objects, and the effect of the 5-methyltetrahydrofolic acid effect CD8 + T cells is detected and explored through flow cytometry; according to the application of 5-methyltetrahydrofolic acid to the treatment of the CD8 + T cells, the 5-methyltetrahydrofolic acid is found to have an inhibition effect on activation and proliferation of the effect CD8 + T cells, a new thought is provided for a disease treatment scheme mainly based on the targeting effect CD8 + T cells, and the 5-methyltetrahydrofolic acid is expected to become a novel treatment scheme aiming at autoimmune diseases caused by the effect CD8 + T cells and has very wide market prospects and great significance.

The invention belongs to the technical field of biological medicines, and particularly relates to engineered platelets, a preparation method thereof and application of the engineered platelets in type 1 diabetes mellitus. According to the engineering blood platelet, PD-L1 protein, PD-L2 protein, BTLA protein and Galectin-9 protein are overexpressed, and the engineering blood platelet is prepared by adopting a cell factor IFN-gamma to stimulate megakaryocyte. Experiments find that engineered platelets over-expressing PD-L1, PD-L2, BTLA and Galectin-9 molecules can accumulate in inflamed pancreatic tissues and inhibit the activity of pancreatic autoreactive T cells, so that beta-cells producing insulin are protected from being attacked, the beta-cells can be rescued by intervening an immune system, insulin secretion is recovered, and the effect of preventing and treating insulin is achieved. Therefore, the blood sugar of the NOD mouse is kept at a normal level, the treatment of newborn type 1 diabetes is realized, and the medicine has a very good treatment effect when being applied to the treatment of diabetes.

The invention provides a traditional Chinese medicine composition for treating or improving sicca syndrome, and belongs to the technical field of traditional Chinese medicine pharmacy. According to the traditional Chinese medicine composition, radix asparagi, lilies and mulberries are used as monarch drugs, honeysuckle stems, pipewort, juncus roemerianus and codonopsis pilosula are used as ministerial drugs, turmeric and rhizoma atractylodis are used as adjuvant drugs, liquorice is used as conductant drugs, and all the drugs are combined to achieve the effects of nourishing yin, moistening dryness, clearing heat, dredging collaterals, replenishing qi, invigorating the spleen, activating blood and improving eyesight. The traditional Chinese medicine composition can significantly reduce the water intake of NOD mice, increase the saliva volume of the NOD mice, significantly reduce the levels of inflammatory factors TNF-alpha, IL-17 and IL-1beta in serum of the NOD mice, improve the gland structure and lymphocyte infiltration condition in submaxillary gland tissue of the NOD mice, and relieve submaxillary gland injury. Besides, the traditional Chinese medicine composition can remarkably reduce ESSDAI and ESSPRI scores of sicca syndrome patients and improve the clinical symptoms such as mouth dryness, eye dryness and salivary gland swelling of the patients, has high clinical treatment total effective rate and can be used as a medicine for treating the sicca syndrome to be further developed and researched.

The invention discloses folic acid, a composition containing the folic acid and application of the folic acid. It is found and verified that folic acid can be used for increasing the number of NKG2A positive DNT cells and treating type 1 diabetes for the first time, a new direction is provided for treatment of type 1 diabetes, and the folic acid has good clinical transformation prospects. According to the invention, the folic acid and the anti-CD3 monoclonal antibody are used for preparing a composition, and the folic acid and the anti-CD3 monoclonal antibody can form a complementary synergistic effect in the aspects of enhancing immune tolerance and inhibiting autoimmunity in treatment; the combined application of the folic acid and the anti-CD3 monoclonal antibody can more effectively prevent the occurrence and development of the type 1 diabetes, reverse the hyperglycemia of the type 1 diabetes and reduce the severity of islet inflammation of NOD mice without influencing the weight of the mice, and provides a new research direction for preparing more efficient and safer type 1 diabetes medicines.

This invention discloses the application of geraniol in the preparation of a drug for treating Sjögren's syndrome. In vivo experiments using a NOD mouse model of Sjögren's syndrome demonstrated that geraniol treatment significantly improved salivary secretion disorders and reduced abnormally high water intake in the mice; significantly reduced lymphocyte infiltration in salivary gland tissue, improved glandular pathological damage, downregulated the levels of characteristic autoantibodies (Anti-SSA / Ro and Anti-SSB / La) in serum, upregulated the expression levels of AQP5 and AR, and reduced organ indices in salivary glands, spleen, and thymus tissue, comprehensively improving dry mouth symptoms in mice. In vitro experiments also showed that geraniol treatment upregulated the expression levels of AQP5 and AR. Therefore, this invention provides the application of geraniol in the preparation of a drug for treating Sjögren's syndrome, which has the advantages of significant efficacy and addressing both the symptoms and root cause, and possesses good clinical application prospects.

The application discloses application of dihydroeugenol in preparation of a medicine for treating Sjogren's syndrome. Through in-vivo experiments of a Sjogren's syndrome model of NOD mice, it is proved that after dihydroeugenol treatment, the saliva secretion disorder of the Sjogren's syndrome model mice can be significantly improved, the abnormally increased water consumption can be reduced, the lymphocyte infiltration of the salivary gland tissue can be significantly reduced, the pathological damage of the gland can be improved, the level of the characteristic autoantibody (Anti-SSA / Ro and Anti-SSB / La) in serum can be lowered, the expression level of AQP5 and AR can be raised, the organ index of the salivary gland, spleen and thymus tissue can be reduced, and the dry mouth symptom of the mice is comprehensively improved. In-vitro experiments also show that after dihydroeugenol treatment, the expression level of AQP5 and AR can be raised. Therefore, the application of dihydroeugenol in preparation of the medicine for treating Sjogren's syndrome has the advantages of significant curative effect, treating both the symptoms and the root cause, and good clinical application prospect.